
## Joleen T White

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9666502/publications.pdf Version: 2024-02-01



LOLFEN T WHITE

#	Article	IF	CITATIONS
1	Transthyretin Aggregation under Partially Denaturing Conditions Is a Downhill Polymerizationâ€. Biochemistry, 2004, 43, 7365-7381.	2.5	303
2	An Engineered Transthyretin Monomer that Is Nonamyloidogenic, Unless It Is Partially Denaturedâ€. Biochemistry, 2001, 40, 11442-11452.	2.5	219
3	D18G Transthyretin Is Monomeric, Aggregation Prone, and Not Detectable in Plasma and Cerebrospinal Fluid: A Prescription for Central Nervous System Amyloidosis?â€. Biochemistry, 2003, 42, 6656-6663.	2.5	117
4	Stability: Recommendation for Best Practices and Harmonization from the Global Bioanalysis Consortium Harmonization Team. AAPS Journal, 2014, 16, 392-399.	4.4	58
5	Timeâ€Varying Clearance and Impact of Disease State on the Pharmacokinetics of Avelumab in Merkel Cell Carcinoma and Urothelial Carcinoma. CPT: Pharmacometrics and Systems Pharmacology, 2019, 8, 415-427.	2.5	53
6	Strategies to Determine Assay Format for the Assessment of Neutralizing Antibody Responses to Biotherapeutics. AAPS Journal, 2016, 18, 1335-1350.	4.4	47
7	Repeated intrathecal injections of recombinant human 4-sulphatase remove dural storage in mature mucopolysaccharidosis VI cats primed with a short-course tolerisation regimen. Molecular Genetics and Metabolism, 2010, 99, 132-141.	1.1	34
8	Intrathecal recombinant human 4-sulfatase reduces accumulation of glycosaminoglycans in dura of mucopolysaccharidosis VI cats. Pediatric Research, 2012, 71, 39-45.	2.3	31
9	Biodistribution and pharmacodynamics of recombinant human alpha-l-iduronidase (rhIDU) in mucopolysaccharidosis type I-affected cats following multiple intrathecal administrations. Molecular Genetics and Metabolism, 2011, 103, 268-274.	1.1	28
10	Incidence, characterization, and clinical impact analysis of peginterferon beta1a immunogenicity in patients with multiple sclerosis in the ADVANCE trial. Therapeutic Advances in Neurological Disorders, 2016, 9, 239-249.	3.5	27
11	R104H may suppress transthyretin amyloidogenesis by thermodynamic stabilization, but not by the kinetic mechanism characterizing T119 interallelic trans-suppression. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2006, 13, 57-66.	3.0	22
12	Pharmacokinetics and pharmacodynamics of peginterferon betaâ€1a in patients with relapsingâ€remitting multiple sclerosis in the randomized <scp>ADVANCE</scp> study. British Journal of Clinical Pharmacology, 2015, 79, 514-522.	2.4	20
13	Development, Validation, and Clinical Implementation of an Assay to Measure Total Antibody Response to Naglazyme® (Galsulfase). AAPS Journal, 2008, 10, 363-372.	4.4	17
14	Understanding and mitigating impact of immunogenicity on pharmacokinetic assays. Bioanalysis, 2011, 3, 1799-1803.	1.5	16
15	Immunogenicity Risk Assessment for PEGylated Therapeutics. AAPS Journal, 2020, 22, 35.	4.4	13
16	Comparison of Neutralizing Antibody Assays for Receptor Binding and Enzyme Activity of the Enzyme Replacement Therapeutic Naglazyme® (Galsulfase). AAPS Journal, 2008, 10, 439-449.	4.4	12
17	Immunogenicity Risk Assessment for Multi-specific Therapeutics. AAPS Journal, 2021, 23, 115.	4.4	10
18	Free and total biotherapeutic evaluation in chromatographic assays: interference from targets and immunogenicity. Bioanalysis, 2012, 4, 2401-2411.	1.5	7

#	Article	IF	CITATIONS
19	Immunogenicity evaluation strategy for a second-generation therapeutic, PEC-IFN-β-1a. Bioanalysis, 2015, 7, 2801-2811.	1.5	6
20	Incurred sample reproducibility and stability assessment in a cell-based drug concentration assay. Bioanalysis, 2015, 7, 1347-1353.	1.5	2
21	Strategies for method comparison when changes in the immunogenicity method are needed within a clinical program. Bioanalysis, 2020, 12, 431-443.	1.5	2